Cerebral blood flow assessed with phase-contrast MRI during blood pressure changes with noradrenaline and labetalol: a trial in healthy volunteers.
Johan BirnefeldKarl PeterssonAnders WåhlinAnders EklundElin BirnefeldSara QvarlanderMichael F HaneyJan MalmLaleh ZarrinkoobPublished in: Anesthesiology (2023)
In healthy awake subjects, increasing MAP using intravenous noradrenaline decreased cerebral blood flow and CO. This data does not support inducing hypertension with noradrenaline to increase cerebral blood flow. Cerebral blood flow was unchanged when decreasing MAP using labetalol.
Keyphrases
- cerebral blood flow
- blood pressure
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- clinical trial
- heart rate
- high dose
- randomized controlled trial
- electronic health record
- metabolic syndrome
- type diabetes
- machine learning
- deep brain stimulation
- adipose tissue
- artificial intelligence
- blood glucose
- glycemic control